Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Invested Capital: 2017-2025

Historic Invested Capital for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $1.1 billion.

  • Crinetics Pharmaceuticals' Invested Capital rose 28.71% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 28.71%. This contributed to the annual value of $1.3 billion for FY2024, which is 145.74% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Invested Capital of $1.1 billion as of Q3 2025, which was down 8.48% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Invested Capital ranged from a high of $1.3 billion in Q4 2024 and a low of $149.5 million during Q1 2021.
  • Moreover, its 3-year median value for Invested Capital was $833.0 million (2024), whereas its average is $816.6 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Invested Capital tumbled by 34.19% in 2023, and later soared by 226.92% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Invested Capital (Quarterly) stood at $331.9 million in 2021, then dropped by 4.70% to $316.3 million in 2022, then surged by 70.43% to $539.1 million in 2023, then spiked by 145.74% to $1.3 billion in 2024, then rose by 28.71% to $1.1 billion in 2025.
  • Its Invested Capital stands at $1.1 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.3 billion for Q1 2025.